Necrostatin-34 is primarily used as a potent and selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), making it a valuable tool in the study of necroptosis, a regulated form of cell death. It is widely applied in research settings to investigate the role of necroptotic pathways in various disease models, including neurodegenerative disorders, ischemic injuries, inflammatory diseases, and organ damage. By blocking RIPK1 activity, Necrostatin-34 helps reduce cell death and inflammation in experimental systems, offering insights into potential therapeutic strategies for conditions where uncontrolled cell death contributes to pathology. Its use in preclinical models has supported the development of novel treatments targeting cell death and immune signaling pathways.